Literature DB >> 9720263

Structure-based drug design.

L M Amzel1.   

Abstract

Most of the techniques used in structure-based drug design have experienced significant improvements in the past few years, resulting in a marked enhancement of the speed and the efficacy of this approach. At the same time, it was thought that the future of drug design lay in strategies involving solely combinatorial chemistry. It is becoming evident, however, that the development of future drugs will use a combination of methods that will contain a major component of structure-based design.

Mesh:

Substances:

Year:  1998        PMID: 9720263     DOI: 10.1016/s0958-1669(98)80009-8

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  8 in total

1.  REdiii: a pipeline for automated structure solution.

Authors:  Markus Frederik Bohn; Celia A Schiffer
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2015-04-24

2.  Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans.

Authors:  Cynthia L David; Harold E Smith; Deborah A Raynes; Elizabeth J Pulcini; Luke Whitesell
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

3.  Basic research in HIV vaccinology is hampered by reductionist thinking.

Authors:  Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2012-07-09       Impact factor: 7.561

4.  A machine learning approach towards the prediction of protein-ligand binding affinity based on fundamental molecular properties.

Authors:  Indra Kundu; Goutam Paul; Raja Banerjee
Journal:  RSC Adv       Date:  2018-03-28       Impact factor: 4.036

Review 5.  Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.

Authors:  Marc H V Van Regenmortel
Journal:  Int J Mol Sci       Date:  2016-09-21       Impact factor: 5.923

6.  Identifying Ortholog Selective Fragment Molecules for Bacterial Glutaredoxins by NMR and Affinity Enhancement by Modification with an Acrylamide Warhead.

Authors:  Ram B Khattri; Daniel L Morris; Stephanie M Bilinovich; Erendra Manandhar; Kahlilah R Napper; Jacob W Sweet; David A Modarelli; Thomas C Leeper
Journal:  Molecules       Date:  2019-12-30       Impact factor: 4.411

7.  Insight into ligand selectivity in HCV NS5B polymerase: molecular dynamics simulations, free energy decomposition and docking.

Authors:  Tong Li; Matheus Froeyen; Piet Herdewijn
Journal:  J Mol Model       Date:  2009-05-26       Impact factor: 1.810

8.  Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma.

Authors:  Sun Yang; Frank L Meyskens
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.